Canine separation anxiety is one of the most commonly reported behavioral conditions in veterinary practice. Characterized by distress, destructive behavior, vocalization, and escape attempts when left alone, it can strain the human–animal bond and, in severe cases, lead to relinquishment or euthanasia. To address this challenge, Simpson, Landsberg, Clark, and colleagues evaluated whether combining pharmacological support with structured behavioral strategies could offer a reliable treatment approach.
The study assessed the use of Reconcile (fluoxetine) administered at 1–2 mg/kg/day alongside a standardized behavior management plan. Results showed clear clinical improvement in dogs receiving the combined treatment, demonstrating reduced anxiety-related behaviors and improved coping during owner absence.
Importantly, the chewable, beef-flavored formulation of Reconcile was found to be highly palatable, simplifying daily administration and supporting long-term treatment adherence. Safety evaluations indicated that the medication was well tolerated, with no unexpected adverse effects.
This research provides veterinarians and dog owners with strong evidence that integrating behavior modification techniques with pharmacological intervention can produce more robust outcomes than behavior management alone. It underscores the value of a multimodal approach for conditions rooted in emotional dysregulation and attachment-related stress.
By combining targeted medication with structured behavioral guidance, practitioners can better support dogs struggling with separation anxiety, enhancing quality of life for both pets and their caregivers.
Source: Simpson, B. S., Landsberg, G., Hunthausen, W., Ackerman, L., Miller, R., Robertson-Plouch, C., … & Clark, T. (2007). Effects of Reconcile (fluoxetine) chewable tablets plus behavior management for canine separation anxiety. Veterinary Therapeutics: Research in Applied Veterinary Medicine.
